Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.

Autor: Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: gabriel9@snu.ac.kr., Taszner M; Department of Haematology and Transplantology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland., Novelli S; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Cho SG; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Villasboas JC; Mayo Clinic, Rochester, USA., Merli M; Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Jiménez-Ubieto A; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Tessoulin B; Hematology Department, Nantes University Hospital, Nantes, France., Poon LM; Hematology Oncology National University Hospital, Singapore, Singapore., Tucker D; Department of Hematology, Royal Cornwall Hospital, Truro, UK., Walewski J; Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw, Poland., Yi S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Song Y; Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China., Chong G; Department of Medical Oncology, and Clinical Haematology, Olivia Newton-John Cancer Centre, Heidelberg, Australia., Bachy E; Department of Hematology, Lyon Sud Hospital, Lyon, France; Lymphoma Immuno-Biology (LIB) team, Inserm U1111, CIRI, Lyon, France., Guidez S; Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, France., Alonso A; Hospital Universitario Quiron Salud Madrid, Madrid, Spain., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, USA., Zhang W; Hematology Department, Peking Union Medical College Hospital, Beijing, China., Magnano L; Hematology Department, Hospital Clínic of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Iskierka-Jażdżewska E; Copernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland., Tani M; Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy., Shen B; Regeneron Pharmaceuticals, Inc., Tarrytown, USA., Uppala A; Regeneron Pharmaceuticals, Inc., Tarrytown, USA., Zhu M; Regeneron Pharmaceuticals, Inc., Tarrytown, USA., Shariff S; Regeneron UK Ltd., Uxbridge, UK., Brouwer-Visser J; Regeneron Pharmaceuticals, Inc., Tarrytown, USA., Chaudhry A; Regeneron Pharmaceuticals, Inc., Tarrytown, USA., Mohamed H; Regeneron Pharmaceuticals, Inc., Tarrytown, USA., Ambati S; Regeneron Pharmaceuticals, Inc., Tarrytown, USA., Luminari S; Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Nov; Vol. 35 (11), pp. 1039-1047. Date of Electronic Publication: 2024 Aug 13.

The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.

Autor: Zaucha JM; Gdynia Oncology Center, Gdynia.; Departments of Oncological Propedeutics.; Hematology and Transplantology, Medical University of Gdańsk, Gdańsk., Malkowski B; Nuclear Medicine Department, Oncology Center, Bydgoszcz.; Positron Emission Tomography and Molecular Imagining Department, Collegium Medicum N. Copernicus University, Bydgoszcz, Poland., Chauvie S; Medical Physics Department, Santa Croce e Carle Hospital, Cuneo, Italy., Subocz E; Department of Hematology, Military Institute of Medicine, Warszawa., Tajer J; Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Institute, Warszawa., Kulikowski W; Clinical Department of Hematology, Interior Ministry Hospital, Warmia.; Mazury Medical University, Olsztyn., Fijolek-Warszewska A; Affidea Mazovian PET/CT Center, Warszawa, Poland., Biggi A; Nuclear Medicine Department, Santa Croce e Carle Hospital, Cuneo., Fallanca F; Nuclear Medicine Department, San Raffaele Hospital, Milano, Italy., Kobylecka M; Nuclear Medicine Department, Warsaw Medical University, Warszawa., Dziuk M; Nuclear Medicine Department, Military Institute of Medicine, Warszawa., Woszczyk D; Hematology Unit, Regional Hospital, Opole., Rybka J; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw., Kroll-Balcerzak R; Department of Hematology, University Medical School, Poznan., Bergesio F; Medical Physics Department, Santa Croce e Carle Hospital, Cuneo, Italy., Romanowicz A; Department of Hematology, Central Clinical Hospital MSW, Warszawa., Chamier-Cieminska A; Department of Clinical Oncology, Oncology Center, Bydgoszcz., Kurczab P; Poradnia Onkologiczna z Oddzialem Chemioterapii Dziennej NZOZ Mrukmed, Rzeszów., Giza A; Department of Hematology, Jagiellonian University Medical College, Krakow., Lesniewski-Kmak K; Gdynia Oncology Center, Gdynia.; Departments of Oncological Propedeutics.; Hematology and Transplantology, Medical University of Gdańsk, Gdańsk., Zaucha R; Department of Clinical Oncology and Radiotherapy., Swietlik D; Intrafaculty College of Medical Informatics & Biostatistics, Medical University of Gdansk, Poland., Wróbel T; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw., Knopinska-Posluszny W; Clinical Department of Hematology, Interior Ministry Hospital, Warmia.; Mazury Medical University, Olsztyn., Walewski J; Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Institute, Warszawa., Gallamini A; Department of Research, Innovation and Statistics, A. Lacassagne Cancer Center, Nice, France.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Dec 01; Vol. 28 (12), pp. 3051-3057.

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.

Autor: Hoster E; Department of Internal Medicine III, University Hospital Munich, Munich, Germany.; Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany., Geisler CH; Hematology Department, Rigshospitalet, Copenhagen, Denmark., Doorduijn J; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van der Holt B; HOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam, The Netherlands., Walewski J; Department of Lymphoid Malignancies, The Maria Skłodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland., Bloehdorn J; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Ribrag V; Institut Gustave Roussy, Villejuif, France., Salles G; Hospices Civils de Lyon, Université Claude Bernard, Pierre Bénite, France., Hallek M; Department I of Internal Medicine, University of Cologne, Cologne, Germany., Pott C; Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Szymczyk M; Department of Lymphoid Malignancies, The Maria Skłodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland., Kolstad A; Oncology Department, The Norwegian Radium Hospital, Oslo, Norway., Laurell A; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden., Räty R; Department of Hematology, Helsinki University Central Hospital, Helsinki, Finland., Jerkeman M; Department of Oncology, Skane University Hospital, Lund, Sweden., Van't Veer M; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Kluin-Nelemans JC; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Klapper W; Department of Pathology, Hematopathology Section and Lymph Node Registry, University of Kiel, Kiel, Germany., Unterhalt M; Department of Internal Medicine III, University Hospital Munich, Munich, Germany., Dreyling M; Department of Internal Medicine III, University Hospital Munich, Munich, Germany., Hermine O; Department of Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France.; INSERM U1163 and CNRS 8254, Imagine Institute, Université Sorbonne Paris Cité, Paris, France.

Publikováno v: Leukemia [Leukemia] 2016 Jun; Vol. 30 (6), pp. 1428-30. Date of Electronic Publication: 2015 Nov 24.

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Autor: Dreyling M; Department of Medicine III, University of Munich, Munich, Germany., Geisler C; Hematology Clinic, Rigshospitalet, Copenhagen, Denmark., Hermine O; Department of Hematology, Imagine Institute and Descartes University, INSERM U1163 and CNRS ERL 8564, Necker Hospital, Paris, France., Kluin-Nelemans HC; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Le Gouill S; Service d'hématologie Clinique, CHU de Nantes, Université de Nantes, Nantes, France., Rule S; Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK., Shpilberg O; Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel., Walewski J; Department of Lymphoid Malignancies, Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland., Ladetto M; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2014 Sep; Vol. 25 Suppl 3, pp. iii83-92.

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Autor: Ghielmini M; Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland. mghielmini@ticino.com, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2013 Mar; Vol. 24 (3), pp. 561-76. Date of Electronic Publication: 2012 Nov 21.